The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Projected To Reach By 2030?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market has experienced consistent expansion over recent years. Forecasts indicate its expansion from $1.31 billion in 2025 to $1.37 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 4.6%. Factors contributing to its historical growth include the scarcity of specific targeted therapies, a continued dependence on traditional chemotherapy and radiation treatment, insufficient public understanding of her2-positive gastric cancer, limited entry to specialized medical facilities, and the gradual incorporation of immunotherapy.
The market for human epidermal growth factor receptor 2 (her2)-positive gastric cancer is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $1.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.6%. This projected growth is driven by several factors, including the advancement of innovative antibody-drug conjugates, a rise in clinical trials for her2-targeted treatments, improvements in healthcare infrastructure within developing regions, an increase in precision medicine and biomarker testing, and the expansion of ambulatory surgery centers and specialized oncology clinics. Key trends anticipated during this period encompass a greater acceptance of her2-targeted therapies, increased understanding of gastric cancer subtypes, broader application of immunotherapy and monoclonal antibodies, a shift towards personalized treatment strategies, and a strengthened emphasis on early detection and diagnostic screening.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp
Which Key Factors Are Driving The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth?
The escalating adoption of targeted cancer therapy is projected to fuel expansion within the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market moving forward. Targeted therapy, also recognized as personalized medicine, is a therapeutic method that utilizes specific drugs or substances to impede cancer development by concentrating on particular molecules integral to tumor formation. The heightened usage of targeted therapy is largely attributable to advancements in genetic profiling, which facilitate more precise treatments tailored to an individual’s unique tumor characteristics, thereby leading to improved efficacy and fewer side effects. In the context of HER2-positive gastric cancer, targeted therapy operates by directly assailing the HER2 protein, which is overexpressed in these tumors, thus slowing disease progression and enhancing patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a professional membership organization based in the US, the Food and Drug Administration (FDA) approved 16 novel personalized medicines in 2023, comprising 7 drugs for cancer and 3 for various other diseases and conditions, representing an increase from 6 approvals in 2022. Therefore, the increasing embrace of targeted cancer therapy is a significant driver for the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
What Are The Key Segment Divisions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segment Structure?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
Which Trends Are Guiding The Direction Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are concentrating on obtaining approvals for innovative therapies, specifically advanced immunotherapy-enhanced combination regimens. These regimens, which involve integrating immune checkpoint inhibitors with targeted therapy and chemotherapy, aim to significantly improve patient outcomes in first-line treatment settings. The advanced immunotherapy-enhanced combination regimens approach functions by leveraging the body’s immune system, inhibiting programmed death (PD)-1 or programmed death (PD)-L1 interaction while simultaneously targeting HER2 receptors and employing chemotherapeutic agents, thereby amplifying anti-tumor activity and enhancing survival rates. For instance, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), in combination with trastuzumab and chemotherapy, as a first-line treatment for adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death (PD)-L1. This newly approved combination therapy demonstrated substantial improvements in median progression-free survival and overall survival compared to standard regimens. With a higher overall response rate of 73% and a longer median duration of response, the treatment signifies a paradigm shift in managing advanced HER2-positive gastric cancers.
Which Organizations Are Engaged In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Get The Full Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report:
Which Region Holds The Highest Market Share In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market 2026, By The Business Research Company
Gastric Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Gastric Cancer Diagnostic Procedure Market Report 2026
Intestine Cancer Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model